Bristol-Myers Squibb Company (BMY)
USD 56.84
(-1.41%)
USD 56.84
(-1.41%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 19.41 Billion USD | -3.74% |
| 2022 | 19.23 Billion USD | -1.28% |
| 2021 | 20.19 Billion USD | 36.22% |
| 2020 | 5.03 Billion USD | 124.52% |
| 2019 | 7.44 Billion USD | 8.7% |
| 2018 | 6.85 Billion USD | 6.17% |
| 2017 | 6.19 Billion USD | 1.8% |
| 2016 | 4.63 Billion USD | 130.77% |
| 2015 | 2.94 Billion USD | 14.06% |
| 2014 | 3.41 Billion USD | -33.93% |
| 2013 | 4.4 Billion USD | -25.92% |
| 2012 | 3.51 Billion USD | -38.82% |
| 2011 | 7.92 Billion USD | 8.38% |
| 2010 | 7.08 Billion USD | 52.52% |
| 2009 | 6.61 Billion USD | -27.8% |
| 2008 | 6.59 Billion USD | 25.52% |
| 2007 | 4.42 Billion USD | 25.71% |
| 2006 | 3.31 Billion USD | -14.93% |
| 2005 | 4.66 Billion USD | -18.94% |
| 2004 | 5.37 Billion USD | -7.44% |
| 2003 | 5.72 Billion USD | -7.3% |
| 2002 | 4.83 Billion USD | -37.62% |
| 2001 | 5.88 Billion USD | 40.65% |
| 2000 | 6.73 Billion USD | 10.54% |
| 1999 | 5.91 Billion USD | 0.95% |
| 1998 | 5.08 Billion USD | 31.35% |
| 1997 | 5.02 Billion USD | 12.28% |
| 1996 | 4.47 Billion USD | -16.72% |
| 1995 | 4.06 Billion USD | 24.51% |
| 1994 | 3.54 Billion USD | 71.8% |
| 1993 | 2.71 Billion USD | 14.09% |
| 1992 | 2.25 Billion USD | -23.14% |
| 1991 | 3.01 Billion USD | 14.39% |
| 1990 | 2.63 Billion USD | 105.86% |
| 1989 | 1.27 Billion USD | -34.58% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 5.14 Billion USD | 151.17% |
| 2024 Q3 | 4.57 Billion USD | 9.27% |
| 2024 Q1 | 4.44 Billion USD | -291.69% |
| 2023 Q4 | 4.14 Billion USD | -1.59% |
| 2023 Q3 | 4.21 Billion USD | -8.88% |
| 2023 Q2 | 4.62 Billion USD | -9.22% |
| 2023 FY | - USD | -3.74% |
| 2023 Q1 | 5.09 Billion USD | 8.1% |
| 2022 Q4 | 4.71 Billion USD | -11.07% |
| 2022 Q1 | 5.07 Billion USD | 2.28% |
| 2022 Q2 | 5.38 Billion USD | 6.13% |
| 2022 FY | - USD | -1.28% |
| 2022 Q3 | 5.3 Billion USD | -1.6% |
| 2021 Q1 | 5.49 Billion USD | 106.2% |
| 2021 FY | - USD | 36.22% |
| 2021 Q2 | 4.68 Billion USD | -14.75% |
| 2021 Q3 | 5.38 Billion USD | 15.0% |
| 2021 Q4 | 4.96 Billion USD | -7.8% |
| 2020 Q3 | 4.63 Billion USD | -0.49% |
| 2020 Q1 | 3.38 Billion USD | 85.92% |
| 2020 Q2 | 4.66 Billion USD | 37.93% |
| 2020 FY | - USD | 124.52% |
| 2020 Q4 | 2.66 Billion USD | -42.6% |
| 2019 Q4 | 1.81 Billion USD | 271.78% |
| 2019 Q3 | 489 Million USD | -73.95% |
| 2019 Q2 | 1.87 Billion USD | -13.42% |
| 2019 Q1 | 2.16 Billion USD | 36.1% |
| 2019 FY | - USD | 8.7% |
| 2018 Q4 | 1.59 Billion USD | -30.13% |
| 2018 Q1 | 1.82 Billion USD | 92.22% |
| 2018 Q2 | 692 Million USD | -62.14% |
| 2018 FY | - USD | 6.17% |
| 2018 Q3 | 2.28 Billion USD | 229.48% |
| 2017 Q4 | 951 Million USD | -32.6% |
| 2017 FY | - USD | 1.8% |
| 2017 Q3 | 1.41 Billion USD | -14.12% |
| 2017 Q2 | 1.64 Billion USD | -4.09% |
| 2017 Q1 | 1.71 Billion USD | 46.79% |
| 2016 FY | - USD | 130.77% |
| 2016 Q4 | 1.16 Billion USD | -30.16% |
| 2016 Q2 | 1.5 Billion USD | -1.5% |
| 2016 Q3 | 1.67 Billion USD | 10.81% |
| 2016 Q1 | 1.53 Billion USD | 21971.43% |
| 2015 Q2 | 370 Million USD | -74.59% |
| 2015 Q4 | -7 Million USD | -100.77% |
| 2015 Q3 | 915 Million USD | 147.3% |
| 2015 FY | - USD | 14.06% |
| 2015 Q1 | 1.45 Billion USD | 1922.22% |
| 2014 FY | - USD | -33.93% |
| 2014 Q3 | 898 Million USD | 53.77% |
| 2014 Q2 | 584 Million USD | -38.14% |
| 2014 Q1 | 944 Million USD | 1.29% |
| 2014 Q4 | 72 Million USD | -91.98% |
| 2013 FY | - USD | -25.92% |
| 2013 Q4 | 932 Million USD | 7.87% |
| 2013 Q3 | 864 Million USD | -3.14% |
| 2013 Q2 | 892 Million USD | -5.51% |
| 2013 Q1 | 944 Million USD | 45.01% |
| 2012 Q1 | 2.29 Billion USD | 18.55% |
| 2012 Q3 | 600 Million USD | -52.94% |
| 2012 Q2 | 1.27 Billion USD | -44.42% |
| 2012 FY | - USD | -38.82% |
| 2012 Q4 | 651 Million USD | 8.5% |
| 2011 FY | - USD | 8.38% |
| 2011 Q1 | 1.88 Billion USD | 13.97% |
| 2011 Q2 | 2.03 Billion USD | 7.75% |
| 2011 Q3 | 2.03 Billion USD | 0.15% |
| 2011 Q4 | 1.93 Billion USD | -4.82% |
| 2010 Q1 | 1.79 Billion USD | 220.93% |
| 2010 Q3 | 1.66 Billion USD | 3.16% |
| 2010 Q4 | 1.65 Billion USD | -0.66% |
| 2010 FY | - USD | 52.52% |
| 2010 Q2 | 1.61 Billion USD | -10.09% |
| 2009 Q1 | 1.61 Billion USD | 29.9% |
| 2009 Q2 | 1.78 Billion USD | 10.48% |
| 2009 FY | - USD | -27.8% |
| 2009 Q3 | 1.83 Billion USD | 2.86% |
| 2009 Q4 | 559 Million USD | -69.49% |
| 2008 Q4 | 1.24 Billion USD | -21.26% |
| 2008 Q1 | 1.44 Billion USD | -5.55% |
| 2008 Q2 | 1.32 Billion USD | -8.29% |
| 2008 FY | - USD | 25.52% |
| 2008 Q3 | 1.57 Billion USD | 18.76% |
| 2007 Q3 | 973 Million USD | -17.75% |
| 2007 Q1 | 1.06 Billion USD | 3.38% |
| 2007 FY | - USD | 25.71% |
| 2007 Q4 | 1.53 Billion USD | 57.45% |
| 2007 Q2 | 1.18 Billion USD | 10.66% |
| 2006 Q2 | 1.25 Billion USD | 38.3% |
| 2006 FY | - USD | -14.93% |
| 2006 Q1 | 906 Million USD | -19.47% |
| 2006 Q4 | 1.03 Billion USD | 74.96% |
| 2006 Q3 | 591 Million USD | -52.83% |
| 2005 FY | - USD | -18.94% |
| 2005 Q2 | 1.38 Billion USD | 2.29% |
| 2005 Q4 | 1.12 Billion USD | 92.64% |
| 2005 Q3 | 584 Million USD | -57.83% |
| 2005 Q1 | 1.35 Billion USD | 11.17% |
| 2004 Q1 | 1.05 Billion USD | -30.48% |
| 2004 FY | - USD | -7.44% |
| 2004 Q3 | 1.46 Billion USD | -16.61% |
| 2004 Q4 | 1.21 Billion USD | -16.63% |
| 2004 Q2 | 1.75 Billion USD | 65.91% |
| 2003 Q2 | 1.45 Billion USD | 7.93% |
| 2003 Q3 | 1.6 Billion USD | 9.95% |
| 2003 FY | - USD | -7.3% |
| 2003 Q4 | 1.51 Billion USD | -5.18% |
| 2003 Q1 | 1.35 Billion USD | 2.97% |
| 2002 FY | - USD | -37.62% |
| 2002 Q1 | 1.32 Billion USD | -73.47% |
| 2002 Q2 | 1.04 Billion USD | -21.67% |
| 2002 Q3 | 2.14 Billion USD | 105.67% |
| 2002 Q4 | 1.31 Billion USD | -38.77% |
| 2001 FY | - USD | 40.65% |
| 2001 Q1 | 1.87 Billion USD | -6.45% |
| 2001 Q2 | 1.67 Billion USD | -10.31% |
| 2001 Q3 | 1.84 Billion USD | 9.89% |
| 2001 Q4 | 5.01 Billion USD | 171.54% |
| 2000 Q2 | 1.68 Billion USD | -9.65% |
| 2000 Q3 | 2.1 Billion USD | 24.63% |
| 2000 Q4 | 2 Billion USD | -4.71% |
| 2000 Q1 | 1.86 Billion USD | 7.8% |
| 2000 FY | - USD | 10.54% |
| 1999 Q2 | 1.48 Billion USD | -9.8% |
| 1999 FY | - USD | 0.95% |
| 1999 Q4 | 1.73 Billion USD | 3.22% |
| 1999 Q1 | 1.64 Billion USD | 10.49% |
| 1999 Q3 | 1.67 Billion USD | 13.09% |
| 1998 Q3 | 1.5 Billion USD | 14.66% |
| 1998 Q2 | 1.31 Billion USD | -9.47% |
| 1998 FY | - USD | 31.35% |
| 1998 Q4 | 1.48 Billion USD | -1.0% |
| 1998 Q1 | 1.44 Billion USD | 14.93% |
| 1997 Q4 | 1.25 Billion USD | -5.76% |
| 1997 FY | - USD | 12.28% |
| 1997 Q1 | 1.26 Billion USD | 16.56% |
| 1997 Q2 | 1.16 Billion USD | -7.89% |
| 1997 Q3 | 1.33 Billion USD | 14.48% |
| 1996 FY | - USD | -16.72% |
| 1996 Q4 | 1.08 Billion USD | -8.35% |
| 1996 Q3 | 1.18 Billion USD | 13.38% |
| 1996 Q2 | 1.04 Billion USD | -9.28% |
| 1996 Q1 | 1.15 Billion USD | 9.6% |
| 1995 Q4 | 1.05 Billion USD | 0.67% |
| 1995 Q3 | 1.04 Billion USD | 10.23% |
| 1995 Q2 | 948 Million USD | -6.88% |
| 1995 Q1 | 1.01 Billion USD | 22.06% |
| 1995 FY | - USD | 24.51% |
| 1994 Q1 | 908 Million USD | 415.91% |
| 1994 Q4 | 834 Million USD | -12.76% |
| 1994 Q3 | 956 Million USD | 12.21% |
| 1994 Q2 | 852 Million USD | -6.17% |
| 1994 FY | - USD | 71.8% |
| 1993 Q4 | 176 Million USD | -80.42% |
| 1993 FY | - USD | 14.09% |
| 1993 Q1 | 854 Million USD | 554.26% |
| 1993 Q2 | 782 Million USD | -8.43% |
| 1993 Q3 | 899 Million USD | 14.96% |
| 1992 Q4 | -188 Million USD | -121.29% |
| 1992 Q2 | 740 Million USD | -9.76% |
| 1992 Q1 | 820 Million USD | 28.33% |
| 1992 FY | - USD | -23.14% |
| 1992 Q3 | 883 Million USD | 19.32% |
| 1991 Q3 | 849 Million USD | 13.96% |
| 1991 FY | - USD | 16.14% |
| 1991 Q4 | 639 Million USD | -24.73% |
| 1991 Q2 | 745 Million USD | -4.36% |
| 1991 Q1 | 779 Million USD | 45.88% |
| 1990 Q4 | 534 Million USD | -31.19% |
| 1990 FY | - USD | 138.85% |
| 1990 Q2 | 666 Million USD | 1.37% |
| 1990 Q1 | 657 Million USD | 111.43% |
| 1990 Q3 | 776 Million USD | 16.52% |
| 1989 Q4 | -5.74 Billion USD | -347.67% |
| 1989 Q2 | 2.24 Billion USD | -0.93% |
| 1989 Q1 | 2.26 Billion USD | 148.77% |
| 1989 Q3 | 2.32 Billion USD | 3.39% |
| 1989 FY | - USD | -42.03% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbbVie Inc. | 26.35 Billion USD | 26.334% |
| Bristol-Myers Squibb Company Ce | 19.41 Billion USD | 0.0% |
| Johnson & Johnson | 23.72 Billion USD | 18.158% |
| Eli Lilly and Company | 8.56 Billion USD | -126.628% |
| Merck & Co., Inc. | 6.9 Billion USD | -181.121% |
| Novartis AG | 18.28 Billion USD | -6.185% |
| Organon & Co. | 1.43 Billion USD | -1252.159% |
| Pfizer Inc. | 9.55 Billion USD | -103.17% |